Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 2 mg - foam - excipient ingredients: propylene glycol; purified water; emulsifying wax; cetyl alcohol; citric acid monohydrate; disodium edetate; butane; isobutane; propane; steareth-10 - budenofalk foam is indicated in the treatment of active rectal and rectosigmoid disease in ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - suppository, moulded - excipient ingredients: hard fat - treatment of ulcerative proctitis

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr. falk pharma uk ltd - mesalazine - suppository - 1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - budesonide, quantity: 3 mg - capsule, enteric - excipient ingredients: sodium lauryl sulfate; purified talc; lactose monohydrate; ammonio methacrylate copolymer; methacrylic acid copolymer; titanium dioxide; erythrosine; iron oxide red; gelatin; iron oxide black; povidone; triethyl citrate; maize starch; sucrose - budenofalk enteric capsules are indicated for: induction of remission in patients with mild to moderately active crohn's disease affecting the ileum and/or the ascending colon (see clinical trials).

Ireland - English - HPRA (Health Products Regulatory Authority)

dr. falk pharma gmbh - ursodeoxycholic acid - oral suspension - 250 mg/5ml - bile acid preparations; ursodeoxycholic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

dr. falk pharma gmbh - ursodeoxycholic acid - film-coated tablet - 500 milligram(s) - bile acid preparations; ursodeoxycholic acid

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; purified talc; polysorbate 80; hypromellose; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; macrogol 6000 - treatment of chronic cholestatic liver diseases

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr. falk pharma uk ltd - ursodeoxycholic acid - oral suspension - 50mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; purified water; maize starch; titanium dioxide; magnesium stearate; gelatin; colloidal anhydrous silica - the treatment of chronic cholestatic liver diseases.